Introduction
Severe malaria evolves through the interplay between capillaric sequestration of parasitized erythrocytes, a deregulated inflammatory response and hemostasis dysfunction [1] [2] [3] [4] [5] . The responsible molecular mechanisms remain the subject of debate, and identification of the triggering events to this day still constitutes a major open challenge in science. Seminal findings on complement activation in malaria were published in the 1970's. Complement turnover was shown to be triggered in human patients suffering from severe malaria 6 , and experiments in monkeys demonstrated that complement consumption coincided with schizont rupture 7 . Clinical data have now accumulated to show that substantial complement activation occurs in human patients 8 and enhanced early complement activation in experimental human malaria has directly been demonstrated 9 .
Experiments in a murine model of cerebral malaria also suggest a pathogenic role of complement activation. C5 deficiency protects mice against cerebral malaria 10 , in which dysregulation of the terminal complement sequence is apparently centrally involved 11 Hemozoin, which is formed in the digestive vacuole of developing intra-erythrocytic parasites, has emerged as a possible trigger of inflammation. This assumption is primarily based on the fact that hematin, considered to represent the synthetic analog of hemozoin 12 , provokes inflammatory responses in macrophages 13, 14 and activates the alternate complement pathway 15 .
Also suggestive is the finding that malarial pigment colocalizes with fibrin in tissues 16 .
However, when the erythrocytic schizonts rupture, the malarial pigment is still surrounded by the membrane of the digestive vacuole and it is the organelle rather than free hemozoin that naturally gains contact with the host environment 17, 18 .
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We have recently reported that when parasitized erythrocytes rupture in blood, the DVs are rapidly phagocytosed by polymorphonuclear granulocytes (PMN) 19 . Phagocytosis only occurred in active serum and complement factor C3 was found attached to the surface of the organelle. It followed that the DV might directly activate complement and experiments were performed to explore this possibility. These led to novel findings that are reported herein. It is shown that the DV is endowed with the capacity to dually activate the alternative complement and the intrinsic clotting pathway. Possibly, efficient opsonization of the DV is initially beneficial because it enables the host to rapidly dispose of the waste product. However, transition to a pathologic state may occur as the disposal system is overrun. Unreigned activation of complement and coagulation may then contribute to events underlying the pathogenesis of severe malaria.
Methods
Banked human blood, group A Rh + RBC, and group A human serum were continuously supplied by the Transfusion Center of the University Medical Center Mainz. Aliquots of human serum were stored at -20°C until use. Serum was heat-inactivated for 30 min, 56°C, for use in routine parasite culture. Active serum was used where indicated.
from Invitrogen, Karlsruhe, Germany. Monoclonal antibody against RBC band 3 protein, protease inhibitor E64 (L-trans-epoxy-succinyl-leucylamido-(4-guanidino)butane), Hoechst 33342 and Low molecular weight-dextran sulfate (LMW-DXS; MW5000) were purchased from Sigma (Taufkirchen, Germany).
P. falciparum culture and isolation of DVs and merozoites. P. falciparum clone 3D7 was maintained as a synchronous continuous culture and digestive vacuoles were isolated and banked in 50% glycerol at -20°C as described 19 . DVs were enumerated using a hematocytometer (CELL-DYN Ruby, Abbott, Wiesbaden, Germany; Software version 2.0ML). Hemozoin was isolated as described 19 , and heme was quantified by measuring absorbance at 405 nm as described 15 .
To isolate merozoites, cultures were tightly synchronized twice with a 4 h lap using 5%
sorbitol. Naturally liberated merozoites and DVs were isolated from the supernatants of enriched cultures as above. DVs were first selectively sedimented by centrifugation at 2000 rpm for 5 min and the merozoites were then obtained by subsequent centrifugation at 5000 rpm for 5 min in a table top centrifuge. Merozoites were washed three times with RPMI and stored frozen at -20°C.
Isolation of parasitophorous vacuole membrane-enclosed merozoite structures (PEMS).
Enriched, late stage pRBC cultures were suspended to 0.2% hematocrit in culture medium containing 10% inactivated serum in the presence of 15 µM E64 for approximately 8 h as described 23 . The culture was centrifuged at 250xg for 5 min to remove intact cells. The supernatant was then centrifuged at 1600 x g for 5 min to remove intact late schizonts. The closely monitored for hemolysis and, immediately after the majority of schizonts ruptured, were centrifuged at 800 rpm for 5 min. The supernatants were centrifuged at 5000 rpm for 10 min in a Sorvall RC2B centrifuge to sediment the merozoites and DVs. Pellets were resuspended in RPMI and centrifuged twice at 2000 rpm for 1 min in a table top centrifuge to remove the RBC. Merozoites and DVs were then sedimented at 5000 rpm for 5 min. Pellets were resuspended in RPMI and thin smears were prepared on glass slides, air-dried and fixed with methanol for 10 seconds or in 2% paraformaldehyde for 10 min at room temperature and stained with anti-C3c or anti-C5b-9 as described below.
Staining of isolated DVs. DVs were incubated with 10% active human serum for 1 h at 37°C, or with 10% inactive serum as controls. DVs were washed with PBS and thin smears were made on glass slides. After fixation, the slides were washed with PBS and then blocked in 3%
BSA for 1 h at room temperature. The slides were washed and incubated with rabbit polyclonal C3c antibody (1:250 dilution), monoclonal anti-human C5b-9 (1:250 dilution), monoclonal anti-human band 3 (1:1000 dilution) or monoclonal anti-MSP1 (1:100 dilution) in blocking buffer for 1 h at room temperature. Non-immune rabbit serum and isotype- 
Statistical analysis
The assumptions for normality and equal variance were verified with SigmaStat 3.1 software (Erkrath, SYSSTAT, Germany). Dependent on the experiment either Repeated Measure ANOVA or One-Way ANOVA was followed by the Bonferroni t test. All results represent mean ± SD of at least three independent experiments, if not indicated else wise. P values of < 0.05 were classified as statistically significant.
Results

Complement activation occurs on the surface of DVs but not on merozoites
In vitro culture of P. falciparum was undertaken conventionally and late stage parasitized RBC (pRBC) were enriched ( Figure 1A , Giemsa stain). BCECF-AM, a membrane-diffusible acetylated carboxyfluoresceine derivative, becomes entrapped intracellularly after its cleavage by cytoplasmic esterases that are absent in RBC but present in nucleated cells and DVs.
Entrapment occurs only when an intact biological membrane is present to limit its egress from the respective compartment. Gratifyingly, we found that merozoites and DVs could both be stained and were then clearly distinguishable from each other ( Figure 1B ). As to be expected, hemozoin characterized the DV while Hoechst 33342 stained merozoites but not the DVs ( Figure 1C ). DVs and merozoites could thus be easily distinguished. More importantly, intactness of the DV membrane, simply probed with the fluorescent dye, would subsequently emerge as the decisive element underlying the singular biological properties of the DV reported herein.
Naturally liberated DVs were isolated from supernatants of hemolysed pRBC. As expected from the literature 27 , they presented as platelet-sized particles that could be enumerated in a hematocytometer ( Figure 1D ). Staining with BCECF-AM could still be undertaken following their isolation and storage at -20°C in glycerol ( Figure 1E ), attesting to the remarkable stability of their membranes. Staining for DNA was negative ( Figure 1F ). In order to exclude potential contaminations of the DV preparation either with erythrocyte or merozoite fragments, the presence of the RBC anion transporter (band 3) and the merozoite surface protein 1 (MSP1) was analysed. The band 3 protein was not detectable by immunofluorescence on the DVs surface ( Figure 1G ). Instead, staining could only be observed on erythrocytes when these were artificially added as controls ( Figure 1H ). This finding was confirmed by immunoblot analysis demonstrating the lack of band 3 on DVs as well as on purified merozoites ( Figure 1I , 1J). Presence of MSP1 was examined by Western blots of purified merozoites and DVs. The latter carry the C-terminal 19 kDa fragment of MSP1 but not the full length protein 28 , which was readily detectable on merozoites but virtually absent in the DV preparations ( Figure 1K ).
To determine whether complement activation would occur upon schizont rupture, late stage pRBC were allowed to lyse in the presence of active, non-immune serum, and complement activity, C3 turnover and pRBC hemolysis were recorded ( Figure 2A ). No changes occurred prior to schizont rupture, but onset of hemolysis was accompanied by C3 turnover and a fall in complement activity. These findings accorded with early observations of Glew et al. that complement consumption coincided with schizont rupture in infected monkeys 7 .
In order to identify the activation pathway, schizont rupture was analysed in the presence of 10 mM EGTA/2 mM Mg
2+
, which prevents classical pathway activation. As shown in Figure   2A complement activation indeed occurred and could thus be attributed to the alternative pathway ( Figure 2A , lowest panels). At the same time, these experiments showed that Ca A representative example is shown in Figure 3B . All DVs stained positively for C3 ( Figure   3C ) and C5b-9 ( Figure 3D ). The latter finding was also confirmed by FACS analysis which impressively demonstrated that all DVs stained positive for the terminal complement complex ( Figure 3D , lower panel).
Contact of the intact DV membrane with plasma is required for complement activation
To discern whether direct contact of the DV with plasma was required for complement activation, intact parasitophorous vacuoles and purified hemozoin were compared for their complement activating capacity with DVs prepared from naturally ruptured pRBC or from trophozoites. Parasitophorous vacuoles were prepared by permitting late stage parasitized RBC to lyse in the presence of the protease inhibitor E64 23 . When the released parasitophorous vacuoles membrane-enclosed merozoite structures (PEMS, Figure 4A ) were tested, they were found to be devoid of complement activating properties ( Figure 4D ).
Control experiments showed that E64 itself did not suppress complement activation by isolated DVs. To test whether activation required the presence of an intact DV membrane, DVs were isolated from hemolysis supernatants or from trophozoite-stage infected RBC 27,30 .
The latter were prepared by saponin-lysis of late-stage infected RBC and, as known from the literature 27,30 , such preparations contained some contaminating RBC-membrane debris ( Figure 4B ). Both preparations had similar complement-activating properties which were lost upon sonication, and this finding correlated with detectability of C3 and C5b-9 exclusively on the intact DV surface but never on any surrounding membrane debris (data not shown).
Centrifugation of the sonicates through Percoll led to retrieval of purified dispersed hemozoin crystals ( Figure 4C ), which were also devoid of complement activating properties when tested at concentrations of 10 -1000 µg heme/ml ( Figure 4D ). Thus, activation of complement required direct contact of intact DV membranes with serum and could not be mimicked by isolated hemozoin, which was also found to be devoid of procoagulant activity (data not shown). The fact that unfractionated, sonicated lysates had no activity reiterated that the activating effects could not have derived from protein or DNA contaminants in the DV preparations.
DVs activate the intrinsic clotting pathway
A number of mechanisms involving the extrinsic clotting pathway are mainly being discussed as the cause of hemostasis dysfunction in malaria patients [3] [4] [5] . However, intrinsic pathway activation also appears to be involved 31 and late stage pRBC reportedly support the assembly of multimeric coagulation complexes 32 . We here demonstrate that the DV similarly has direct procoagulant activity.
The intrinsic clotting pathway is routinely tested by determination of activated partial prothrombin time, where an empiric mix of activators is added to citrated plasma and clotting times after recalcification are read. Long clotting times (>400-1000 sec) are observed if the activators are omitted. When DVs were used instead of the activators, dose-dependent shortening of clotting times was observed ( Figure 5A ). These results were corroborated in prothrombinase assays using isolated factors FVa, FII and FXa. In the conventional test, phospholipids are added to provide platforms for Ca 2+ -dependent assembly of the prothrombinase complex FVa/FXa. The phospholipids were here omitted and replaced by DVs, which dose-dependently provoked thrombin formation ( Figure 5B ). Thus, the DV could directly assemble the key convertase of the clotting pathway. As with complement activation, this required only low numbers of DVs corresponding to less than 1% hematocrit.
Prothrombinase assembly is generally mediated via Ca
2+
-bridged interactions with phospholipid head groups. When DVs were treated with phopholipase C, procoagulant activity was indeed destroyed ( Figure 5C ), while complement-activating capacity remained intact (not shown).
For and clotting should indeed contribute to malaria pathogenesis, the existence of a well established inhibitor could be of high interest. Therefore, we tested the effect of LMW-DXS on DV effects. LMW-DXS at concentrations of 10-100 µg/ml effectively inhibited DVdependent activation of the intrinsic clotting pathway ( Figure 6A ) and abrogated assembly of prothrombinase complexes ( Figure 6B ). In accord with the literature 36 , somewhat higher concentrations were required to block complement activation, but effects were also apparent at 100 µg/ml ( Figure 6C ).
DVs activate the alternative complement pathway and produce clinical symptoms in rats
Animal experiments were performed to obtain an indication whether the DVs also activated complement in vivo and might contribute to the development of clinical symptoms. These experiments were performed in rats because alternative complement pathway activity is extremley low in mice. Alternative pathway activity was determined using rabbit erythrocytes as targets. The first group of animals received 4-5 x 10 9 DVs injected into the tail vein.
Nociceptive responses were determined with the hot plate test and behavioral reactions were filmed. Acute onset of clinical symptoms was observed in all cases, commencing 1-2 min after injection. Animals became lethargic, exhibited diminished reactions to tactic and acoustic stimuli, and nociceptive responses were retarded ( Figure 7A and Supplement Video 1). Alternative complement pathway activity was reduced by > 85% in all animals (n = 5).
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The second group of animals received the same batch and dose of DVs that, however, were sonicated prior to application. Alternative complement pathway activity remained unchanged in the serum of these animals, which strikingly also developed no clinical symptoms (n = 3) ( Figure 7A and Supplement Video 2). The third group of animals received 6 mg LMW-DXS intraperitoneally, which led to > 65% reduction in alternative pathway complement activity in plasma after 45-60 min. Remarkably, all animals (n = 4) were fully protected from the detrimental effects of DV-infusion ( Figure 7A and Supplement Video 3).
Rapid cellular uptake of DVs by mononuclear cells in rats after intravenous injection
To trace the fate of the DVs, rats were sacrified after 4-6 h. DVs and PMN were rarely Collectively, these data demonstrated that free DVs are rapidly taken up by mononuclear cells.
Discussion
Although complement activation and coagulation defects during P. falciparum malaria have been recognized for decades, no single entity of parasite origin has yet been identified that might directly be involved in triggering these events. Rupture of each P. falciparum parasitized erythrocyte is accompanied by release of one DV into the circulation. Yet, while Figure 3A, Figures 5A, B) . Thus, increases in the load of DVs as occurring at sites of pRBC sequestration would be expected to simply augment activation of both enzyme cascades. Provocation of clinical symptoms will naturally depend on myriad local factors of the micro-environment, e.g. presence or absence of regulatory factors such as tissue factor and thrombomodulin [1] [2] [3] [4] [5] . Transactivation events occurring between the coagulation system, complement, platelets and blood cells may then pave the way to final disaster.
Our study originated from the observation that rupture of pRBC in active serum led to C3 conversion and to binding of C3b and C5b-9 to the DV, with conspicuous sparing of merozoites. The results were reproduced with isolated DVs, and attachment of C5b-9 indicated its presence in membrane-bound form. Direct contact between the DV membrane and serum was required for activation to take place, and PEMS, in which DVs remained encased within the PVM, were without effect. DVs isolated via saponin-lysis of late-stage infected RBC also activated complement. These preparations contained contaminating membrane material that, however, was not seen to stain positively for C3 or C5b-9. The findings do not entirely exclude that other membranes or organelles may also have complement activating properties. However, these yet remain to be identified. Quite remarkably, isolated hemozoin activated neither complement nor coagulation. This was
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Disruption of the DV membrane destroyed both complement-activating and procoagulant properties. Thus, our findings led to the question what particular membrane characteristics enabled the digestive vacuole but not the merozoite to activate both cascades. Information on the composition and organization of the DV membrane is currently not available. Such analyses are impeded by the fact that entities other than hemozoin are encased within the DV, including lipid bodies of poorly defined composition 38 . However, we found that procoagulant activity was selectively destroyed by phospholipase C treatment and must thus be borne by phospholipid head groups. This finding is not surprising since multimolecular assembly of clotting enzymes is generally promoted by Ca 2+ -bridged interactions with negatively charged phospholipid head groups. It is very likely that, in analogy with other activating surfaces, exposed phospholipid head groups similarly play essential roles. Further studies are needed to identify the responsible moieties, but the key recognition remains that an intact membrane is required for the DV to unfold both its complement-activating and procoagulant properties.
The latter are intrinsically borne and not dependent on any interaction with platelets. Clotting was triggered in platelet-free plasma, and thrombin could be generated directly by incubating purified DVs with FXa and prothrombin.
Why complement activation in non-immune serum occurs exclusively on the DV remains to to be clarified. GPI-anchored proteins including complement inhibitors 39, 40 have been shown to shuttle from the RBC to the parasitophorous vacuole membrane [41] [42] [43] [44] , and the possibility is being examined whether they further be recruited to the merozoite surface to shield the parasite from complement attack. In any event, the DV might serve as a decoy for central host defense elements. Indeed, we have found that complement activation marks the DV for selective phagocytosis by neutrophil granulocytes, while merozoites are left free to reinvade cells. This situation was found to persist in the presence of serum from malarial patients 19 .
Possibly, alternative pathway activation plays a first role in mediating selective opsonization of DVs in non-immune serum. As specific antibodies appear, classical pathway activation may be triggered on both the DVs and merozoites. The density of activated complement components will consequently remain higher on the DV thereby sustaining its preferential phagocytosis.
When DVs were injected into rat tail veins, complement consumption occurred within minutes and the animals became lethargic and behavioral responses were impaired. The clinical symptoms possibly derived from systemic activation of endothelial and phagocytic cells with release of inflammatory molecules and mediators, which would be expected to occur following triggering of the clotting 5 and alternative complement pathway 45 . The effects of bolus DV-infusions were transient, reminiscent of LPS-injection, which also provokes systemic inflammatory responses and complement activation 46 . Termination of the reaction to DVs might be explained by their rapid clearance by phagocytic cells. Indeed, PMN were rarely seen in the bloodstream of the animals, and the massive uptake of DVs by tissue phagocytes was impressive. At the onset of malaria infections, the low load of DVs is perhaps first cleared by PMN. As the clearance capacity is overrun, tissue macrophages may come into play. Malaria pigment is present in these cells in human patients 16, 47 , and our finding that isolated DVs reside in tissue macrophages within hours after intravenous application also Heterozygotes are not prone to suffer from bacterial infections because serum complement activity is only lowered, but perhaps these individuals are protected against the effects of complement overactivation that lead to severe malaria.
If the major tenets of our hypothesis turn out to be correct, strategies to inhibit DV-dependent activation of complement and coagulation might have therapeutic potential. Activation of both cascades was found to be inhibited by LMW-DXS. In contrast to heparin, LMW-DXS does not cause bleeding complications and is well tolerated in humans. Indeed, the agent caused no side effects in rats but protected the animals from the harmful effects of very high doses of DV infusion. The agent was applied at the same concentrations as previously used in transplantation models
36
. LMW-DXS has also been reported to suppress merozoite reinvasion 52 and may therefore simultaneously fulfill dual beneficial functions.
It is intriguing that, having served its physiological purpose in the life cycle of the parasite, the DV should be endowed with the capacity to activate the two archaic enzyme cascade systems of the blood into which it is cast. Perhaps these events initially serve a protective
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function by enabling the infected host to rapidly remove alien waste material. However, pathological consequences may evolve when the disposal machinery suffers overload, these events then contributing to the evolution of severe malaria. Future studies should disclose whether a novel determinant of parasite pathogenicity has been discovered that might also be targeted for therapy to the benefit of patients suffering from what still remains one of the most prevalent life-threatening diseases in the world. Neither PEMS nor isolated hemozoin had complement activating capacity. One representative assay out of three independent experiments is shown with SD from triplicate determinations. 
